{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:10:08Z","timestamp":1790075408056,"version":"4.0.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ctrv.2020.101996","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T21:34:50Z","timestamp":1582839290000},"page":"101996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["The force of HER2 \u2013 A druggable target in NSCLC?"],"prefix":"10.1016","volume":"86","author":[{"given":"M.","family":"Jebbink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.101996_b0005","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101996_b0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.biophys.37.032807.125829","article-title":"Structure-based view of epidermal growth factor receptor regulation","volume":"37","author":"Ferguson","year":"2008","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.ctrv.2020.101996_b0015","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ctrv.2020.101996_b0020","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/cncr.20957","article-title":"Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis","volume":"103","author":"Nakamura","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2020.101996_b0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/JTO.0b013e3181f26266","article-title":"The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data","volume":"5","author":"Liu","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2011.01.014","article-title":"Prognostic and predictive implications of HER2\/ERBB2\/neu gene mutations in lung cancers","volume":"74","author":"Tomizawa","year":"2011","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0035","doi-asserted-by":"crossref","first-page":"e0171280","DOI":"10.1371\/journal.pone.0171280","article-title":"The frequency and clinical impact of HER2 alterations in lung adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2015.02.002","article-title":"HER2-positive metastatic breast cancer: a changing scenario","volume":"95","author":"Mustacchi","year":"2015","journal-title":"Critical Rev Oncol\/Hematol"},{"issue":"4785","key":"10.1016\/j.ctrv.2020.101996_b0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10120-012-0179-9","article-title":"Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment","volume":"16","author":"Shitara","year":"2013","journal-title":"Gastric Cancer"},{"issue":"9742","key":"10.1016\/j.ctrv.2020.101996_b0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0060","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1756-9966-28-97","article-title":"The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"28","author":"Calikusu","year":"2009","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazieres","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.101996_b0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ctrv.2020.101996_b0080","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ctrv.2020.101996_b0085","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0090","first-page":"84","article-title":"Targeted therapy in NSCLC driven by HER2 insertions","volume":"3","author":"Peters","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2006.05.023","article-title":"HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2006","journal-title":"Cancer Cell"},{"issue":"7008","key":"10.1016\/j.ctrv.2020.101996_b0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.chest.2019.01.011","article-title":"A prospective cohort study to define the clinical features and outcome of lung cancers harboring HER2 Aberration in Japan (HER2-CS STUDY)","volume":"156","author":"Ninomiya","year":"2019","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0110","doi-asserted-by":"crossref","first-page":"S1830","DOI":"10.1016\/j.jtho.2017.09.513","article-title":"07.13 NGS sequencing based liquid\/tissue biopsy identified coexistence of HER2 amplification and mutation in advanced NSCLC patients","volume":"12","author":"Chen","year":"2017","journal-title":"J Thoracic Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2020.101996_b0115","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2020.101996_b0120","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.101996_b0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lungcan.2014.06.007","article-title":"HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations","volume":"85","author":"Yoshizawa","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2020.101996_b0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2020.101996_b0135","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0140","first-page":"122","article-title":"HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches","volume":"2","author":"Garrido-Castro","year":"2013","journal-title":"Transl Lung Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2020.101996_b0145","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1158\/1078-0432.CCR-18-0991","article-title":"High-throughput functional evaluation of variants of unknown significance in ERBB2","volume":"24","author":"Nagano","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.ctrv.2020.101996_b0150","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0155","article-title":"Germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas","volume":"106","author":"Matsuda","year":"2013","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.101996_b0160","doi-asserted-by":"crossref","unstructured":"Li BT, Zheng T, Ni A, Hellmann MD, Jordan E, Barron D, et al. Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers. 2016;34(15_suppl):e20666-e.","DOI":"10.1200\/JCO.2016.34.15_suppl.e20666"},{"key":"10.1016\/j.ctrv.2020.101996_b0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fonc.2019.00212","article-title":"Detection of ERBB2 (HER2) gene amplification events in cell-free DNA and response to anti-HER2 agents in a large Asian cancer patient cohort","volume":"9","author":"Lee","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/JTO.0b013e318234f0a2","article-title":"Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2\/EGFR copy number gains","volume":"7","author":"Li","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.101996_b0175","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/sj.bjc.6600286","article-title":"Evaluation of HER-2\/neu gene amplification and protein expression in non-small cell lung carcinomas","volume":"86","author":"Hirsch","year":"2002","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2020.101996_b0180","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2005.09.111","article-title":"Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients","volume":"23","author":"Cappuzzo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.101996_b0185","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1586\/14737140.2013.846830","article-title":"HER2 and lung cancer","volume":"13","author":"Landi","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2020.101996_b0190","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","DOI":"10.1038\/nature13385"},{"issue":"14","key":"10.1016\/j.ctrv.2020.101996_b0195","first-page":"5238","article-title":"HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin","volume":"9","author":"Heinmoller","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2020.101996_b0200","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1158\/1078-0432.CCR-05-0636","article-title":"Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials","volume":"11","author":"Press","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2020.101996_b0205","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1097\/JTO.0b013e3181ea510a","article-title":"Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients","volume":"5","author":"Al-Saad","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0210","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-18-0198","article-title":"HER2 deregulation in lung cancer: right time to adopt an orphan?","volume":"24","author":"Cappuzzo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0215","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1172\/JCI117001","article-title":"C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas","volume":"93","author":"Kern","year":"1994","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.ctrv.2020.101996_b0220","first-page":"659","article-title":"Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients","volume":"1","author":"Harpole","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0225","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-17-1875","article-title":"Targeting HER2 aberrations in non-small cell lung cancer with osimertinib","volume":"24","author":"Liu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2020.101996_b0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/JTO.0b013e31816e2ea3","article-title":"Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"3","author":"Kuyama","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2020.101996_b0235","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2020.101996_b0240","first-page":"3323","article-title":"Concordance of HER2 immunohistochemistry and fluorescence in situ hybridization using tissue microarray in breast cancer","volume":"37","author":"Furrer","year":"2017","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2020.101996_b0245","doi-asserted-by":"crossref","first-page":"922","DOI":"10.5858\/arpa.2014-0127-OA","article-title":"Evaluation of HER2\/neu status by immunohistochemistry using computer-based image analysis and correlation with gene amplification by fluorescence in situ hybridization assay: a 10-year experience and impact of test standardization on concordance rate","volume":"139","author":"Sarode","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2020.101996_b0250","article-title":"Pilot evaluation of a HER2 testing in non-small-cell lung cancer","author":"Hotta","year":"2019","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.101996_b0255","first-page":"3239","article-title":"Expression of Her-2\/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents","volume":"7","author":"Bunn","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2020.101996_b0260","first-page":"1850","article-title":"Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival","volume":"7","author":"Brabender","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2020.101996_b0265","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3816\/CLC.2006.n.015","article-title":"Sex differences in the predictive power of the molecular prognostic factor HER2\/neu in patients with non-small-cell lung cancer","volume":"7","author":"Vallbohmer","year":"2006","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jtho.2019.09.006","article-title":"Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R\/T790M-positive non-small cell lung cancer","volume":"15","author":"Hsu","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.101996_b0275","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.101996_b0280","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann Oncol"},{"issue":"99","key":"10.1016\/j.ctrv.2020.101996_b0285","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2020.101996_b0290","doi-asserted-by":"crossref","unstructured":"Altavilla G, Arrigo C, Tomasello C, Santarpia M, Mondello P, Benecchi S, et al. Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs. 2013;31(15_suppl):8047.","DOI":"10.1200\/jco.2013.31.15_suppl.8047"},{"issue":"Supplement_2","key":"10.1016\/j.ctrv.2020.101996_b0295","article-title":"114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study","volume":"30","author":"Xu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101996_b0300","first-page":"LBA50","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0305","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdn635","article-title":"MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients","volume":"20","author":"Cappuzzo","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.101996_b0310","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41416-018-0194-7","article-title":"Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment","volume":"119","author":"de Langen","year":"2018","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2020.101996_b0315","doi-asserted-by":"crossref","first-page":"e1001906","DOI":"10.1371\/journal.pbio.1001906","article-title":"Tracking genomic cancer evolution for precision medicine: the lung TRACERx study","volume":"12","author":"Jamal-Hanjani","year":"2014","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0320","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2020.101996_b0325","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"issue":"7691","key":"10.1016\/j.ctrv.2020.101996_b0330","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2012.47.2787","article-title":"Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors","volume":"32","author":"Gandhi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.101996_b0340","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.lungcan.2015.10.025","article-title":"HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib","volume":"90","author":"Li","year":"2015","journal-title":"Lung Cancer"},{"issue":"suppl_4","key":"10.1016\/j.ctrv.2020.101996_b0345","article-title":"LBA39_Prneratinib (N) with or without temsirolimus (TEM) in patients (PTS) with non-small cell lung cancer (NSCLC) carrying her2 somatic mutations: an international randomized phase II Study","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Greve","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0355","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","article-title":"Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma","volume":"88","author":"De Greve","year":"2015","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2020.101996_b0360","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jtho.2018.07.093","article-title":"Activity of afatinib in heavily pretreated patients with ERBB2 mutation-positive advanced NSCLC: findings from a global named patient use program","volume":"13","author":"Peters","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.101996_b0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.11.030","article-title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","volume":"109","author":"Lai","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.101996_b0370","article-title":"Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma","author":"Fang","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0375","doi-asserted-by":"crossref","first-page":"S1829","DOI":"10.1016\/j.jtho.2017.09.512","article-title":"07.12 Short-term culture of patient derived tumor organoids identify neratinib\/trastuzumab as an effective combination in HER2 mutant lung","volume":"12","author":"Ivanova","year":"2017","journal-title":"Cancer J Thoracic Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.101996_b0380","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2020.101996_b0385","unstructured":"Heymach J, Negrao M, Robichaux J, Carter B, Patel A, et al. Phase II trial of poziotinib for EGFR and HER2 exon 20 mutant NSCLC. In: IASLC 19th world conference on lung cancer (presentation). 2018;September 23\u201326 2018(Toronto, Canada)."},{"issue":"4","key":"10.1016\/j.ctrv.2020.101996_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2020.101996_b0395","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.101996_b0400","article-title":"HER2 exon 20 insertions in non-small cell lung cancer are sensitive to the irreversible Pan-HER receptor tyrosine kinase inhibitor pyrotinib","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"issue":"6924","key":"10.1016\/j.ctrv.2020.101996_b0405","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.ctrv.2020.101996_b0410","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2020.101996_b0415","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2020.101996_b0420","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A Phase II Study of Trastuzumab Emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2020.101996_b0425","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for patients with HER2-mutant lung cancers: results from a Phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2020.101996_b0430","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Supplement_2","key":"10.1016\/j.ctrv.2020.101996_b0435","article-title":"183TiPA phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2020.101996_b0440","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-08-3328","article-title":"Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer","volume":"16","author":"Ross","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2020.101996_b0445","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.20950","article-title":"Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B","volume":"103","author":"Clamon","year":"2005","journal-title":"Cancer"},{"issue":"14 Pt 2","key":"10.1016\/j.ctrv.2020.101996_b0450","doi-asserted-by":"crossref","first-page":"4436s","DOI":"10.1158\/1078-0432.CCR-06-0629","article-title":"Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer","volume":"12","author":"Johnson","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2020.101996_b0455","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-07-0460","article-title":"Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer","volume":"13","author":"Herbst","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0460","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab Emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.101996_b0465","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1476-4598-13-143","article-title":"Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance","volume":"13","author":"Cretella","year":"2014","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2020.101996_b0470","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-017-0653-7","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2020.101996_b0475","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","article-title":"Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)","volume":"14","author":"Dziadziuszko","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:21:41Z","timestamp":1759656101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":95,"alternative-id":["S0305737220300347"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.101996","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The force of HER2 \u2013 A druggable target in NSCLC?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.101996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101996"}}